Taylor Wealth Management Partners lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 204,277 shares of the biopharmaceutical company’s stock after selling 17,103 shares during the period. Halozyme Therapeutics makes up about 1.7% of Taylor Wealth Management Partners’ investment portfolio, making the stock its 20th largest position. Taylor Wealth Management Partners owned about 0.14% of Halozyme Therapeutics worth $2,989,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Cubist Systematic Strategies LLC increased its position in Halozyme Therapeutics by 69.1% in the second quarter. Cubist Systematic Strategies LLC now owns 22,346 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 9,134 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in Halozyme Therapeutics in the third quarter worth $21,690,000. AXA increased its position in Halozyme Therapeutics by 9.5% in the third quarter. AXA now owns 428,217 shares of the biopharmaceutical company’s stock worth $7,781,000 after purchasing an additional 37,108 shares during the last quarter. First Eagle Investment Management LLC increased its position in Halozyme Therapeutics by 2.3% in the third quarter. First Eagle Investment Management LLC now owns 2,173,089 shares of the biopharmaceutical company’s stock worth $39,485,000 after purchasing an additional 48,526 shares during the last quarter. Finally, Swiss National Bank increased its position in Halozyme Therapeutics by 1.6% in the third quarter. Swiss National Bank now owns 226,000 shares of the biopharmaceutical company’s stock worth $4,106,000 after purchasing an additional 3,500 shares during the last quarter. Institutional investors own 83.90% of the company’s stock.
Several brokerages recently weighed in on HALO. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Tuesday, November 13th. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. ValuEngine cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th. Cantor Fitzgerald set a $27.00 price objective on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, Piper Jaffray Companies began coverage on shares of Halozyme Therapeutics in a research note on Thursday, October 18th. They set a “hold” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $20.56.
NASDAQ HALO traded down $0.15 on Monday, hitting $16.10. 30,305 shares of the stock were exchanged, compared to its average volume of 880,530. The company has a quick ratio of 2.96, a current ratio of 3.09 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 35.78 and a beta of 1.72. Halozyme Therapeutics, Inc. has a 52-week low of $13.24 and a 52-week high of $21.48.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The company had revenue of $25.60 million during the quarter, compared to analyst estimates of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. Halozyme Therapeutics’s quarterly revenue was down 59.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.02 earnings per share. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post -0.56 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://theenterpriseleader.com/2019/01/14/taylor-wealth-management-partners-trims-position-in-halozyme-therapeutics-inc-halo.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Further Reading: What are the reasons investors use put options?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.